A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke

Other illness

• Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
• Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
• A mental illness diagnosed according to the DSM-V diagnostic criteria.
• Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
• Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
• A mental illness diagnosed according to the DSM-V diagnostic criteria.
• Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
• Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
• A mental illness diagnosed according to the DSM-V diagnostic criteria.

Other

• Study 1:
• There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm).
• There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
• Unable to cooperate in completing follow-up visits due to geographical or other reasons.
• The patient also participated in other clinical trials.
  • Study 2:
• There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm).
• There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
• Unable to cooperate in completing follow-up visits due to geographical or other reasons.
• The patient also participated in other clinical trials.
  • Study 3:
• There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm).
• There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
• Unable to cooperate in completing follow-up visits due to geographical or other reasons.
• The patient also participated in other clinical trials.

• Study 1:
• Age ≥ 18 years old.
• Acute ischemic stroke within 7 days of onset.
• Sign an informed consent form.
  • Study 2:
• Age ≥ 18 years old.
• Ischemic stroke during recovery period, within 30 days to 1 year of onset.
• Sign an informed consent form.
  • Study 3:
• Age ≥ 18 years old.
• Within 3 years, there are characteristic lesions of cerebral small vessel disease on head MRI or CT, and they meet at least one of the following criteria:
  • Paraventricular or deep white matter hyperintensities, Fazekas total score ≥ 2;
  • Paraventricular or deep white matter hyperintensities, Fazekas total score=1, and at least two vascular risk factors (hypertension, hyperlipidemia, diabetes, current smoking, obesity, history of coronary heart disease, history of stroke).
  • Paraventricular or deep white matter hyperintensities, Fazekas total score=1, with ≥ 1 lacune.
  • New recent subcortical small infarcts.
• Sign an informed consent form.